Seelos Therapeutics Cash on Hand 2010-2022 | SEEL

Seelos Therapeutics cash on hand from 2010 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Seelos Therapeutics Annual Cash on Hand
(Millions of US $)
2021 $79
2020 $16
2019 $10
2018 $0
2017 $6
2016 $2
2015 $4
2014 $12
2013 $22
2012 $15
2011 $7
2010 $10
2009 $0
Seelos Therapeutics Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $62
2021-12-31 $79
2021-09-30 $77
2021-06-30 $87
2021-03-31 $39
2020-12-31 $16
2020-09-30 $8
2020-06-30 $6
2020-03-31 $13
2019-12-31 $10
2019-09-30 $15
2019-06-30 $10
2019-03-31 $11
2018-12-31 $0
2018-09-30 $5
2018-06-30 $7
2018-03-31 $6
2017-12-31 $6
2017-09-30 $8
2017-06-30 $8
2017-03-31 $4
2016-12-31 $2
2016-09-30 $6
2016-06-30 $3
2016-03-31 $7
2015-12-31 $4
2015-09-30 $6
2015-06-30 $8
2015-03-31 $16
2014-12-31 $12
2014-09-30 $16
2014-06-30 $18
2014-03-31 $23
2013-12-31 $22
2013-09-30 $21
2013-06-30 $25
2013-03-31 $14
2012-12-31 $15
2012-09-30 $17
2012-06-30 $18
2012-03-31 $22
2011-12-31 $7
2011-09-30 $9
2011-06-30 $9
2011-03-31 $10
2010-12-31 $10
2010-09-30
2010-06-30 $4
2010-03-31 $3
2009-12-31 $0
2009-09-30 $2
2009-06-30 $3
2009-03-31 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.067B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00